Regional and temporal variation in the treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study

被引:28
作者
Edwards, Christopher John [1 ,2 ]
Campbell, Jennifer [3 ]
van Staa, Tjeerd [3 ,4 ]
Arden, Nigel K. [2 ,5 ]
机构
[1] Univ Hosp Southampton NHS Fdn Trust, Dept Rheumatol, Southampton, Hants, England
[2] Univ Southampton, Southampton, Hants, England
[3] Med & Healthcare Prod Regulatory Agcy, Gen Practice Res Database, London, England
[4] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands
[5] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX1 2JD, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
QUALITY-OF-LIFE; MODIFYING ANTIRHEUMATIC DRUGS; RADIOGRAPHIC PROGRESSION; DISEASE; HEALTH; GLUCOCORTICOIDS; METHOTREXATE; MORTALITY; AGENTS; IMPACT;
D O I
10.1136/bmjopen-2012-001603
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objectives: To describe current disease-modifying antirheumatic drugs (DMARDs) prescription in rheumatoid arthritis (RA) with reference to best practice and to identify temporal and regional trends in the UK. Design: Descriptive, register-based cohort study. Participants: Permanently registered patients aged >= 18 years with a recorded diagnosis of RA between 1 January 1995 and 31 March 2010 and matched controls. Participants with RA were identified through screening of all patients in the General Practice Research Database (GPRD) with a clinical or referral record for RA and at least 1 day of follow-up. Setting: 639 general practices in the UK supplying data to the GPRD. Main outcome measures: Medication prescribing between 3 and 12 months of RA diagnosis by region and time period (1995-1999, 2000-2005 and 2006-April 2010). Results: Of the 35 911 patients in the full RA cohort, 15 259 patients (42%) had incident RA. Analysis of prescribing in incident RA patients demonstrated that between 1995 (baseline) and 2010 there was a substantial increase in DMARD, and specifically methotrexate, prescribing across all regions with a less marked increase in combination DMARD prescribing. Taking 12-month prescribing as a snapshot: DMARD prescribing was 19-49% at baseline increasing to 45-74% by 2006-April 2010; methotrexate prescribing was 4-16% at baseline increasing to 32-60%; combination DMARD prescribing was 0-8% at baseline increasing to 3-17%. However, there was marked regional variation in the proportion of RA patients receiving DMARD regardless of time period. Conclusions: There has been a substantial increase in prescribing of DMARDs for RA since 1995; however, regional variation persists across the UK with relative undertreatment, according to established best practice. Improved implementation of evidence-based best clinical practice to facilitate removal of treatment variation is warranted. This may occur as a result of the implementation of published national guidance.
引用
收藏
页数:7
相关论文
共 26 条
[1]
[Anonymous], 2009, SERV PEOPL RHEUM ART
[2]
[Anonymous], NICE CLIN GUID 79 RH
[3]
THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[4]
Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis [J].
Choy, E. H. S. ;
Smith, C. M. ;
Farewell, V. ;
Walker, D. ;
Hassell, A. ;
Chau, L. ;
Scott, D. L. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (05) :656-663
[5]
Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis. [J].
Choy, EHS ;
Panayi, GS .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :907-916
[6]
The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database [J].
Edwards, CJ ;
Arden, NK ;
Fisher, D ;
Saperia, JC ;
Reading, I ;
Van Staa, TP ;
Cooper, C .
RHEUMATOLOGY, 2005, 44 (11) :1394-1398
[7]
Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis [J].
Finckh, Axel ;
Liang, Matthew H. ;
van Herckenrode, Carmen Mugica ;
de Pablo, Paola .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (06) :864-872
[8]
Don't forget traditional DMARDs [J].
Fleischmann, Roy .
RHEUMATOLOGY, 2011, 50 (03) :429-430
[9]
Similar Effects of Disease-Modifying Antirheumatic Drugs, Glucocorticoids, and Biologic Agents on Radiographic Progression in Rheumatoid Arthritis Meta-Analysis of 70 Randomized Placebo-Controlled or Drug-Controlled Studies, Including 112 Comparisons [J].
Graudal, Niels ;
Jurgens, Gesche .
ARTHRITIS AND RHEUMATISM, 2010, 62 (10) :2852-2863
[10]
Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations [J].
Harrold, Leslie R. ;
Harrington, J. Timothy ;
Curtis, Jeffrey R. ;
Furst, Daniel E. ;
Bentley, Mary Jane ;
Shan, Ying ;
Reed, George ;
Kremer, Joel ;
Greenberg, Jeffrey D. .
ARTHRITIS AND RHEUMATISM, 2012, 64 (03) :630-638